Recent Updates
Recently added Catalysts
GMAB Positive Sentiment

Genmab Announces Financial Results for the First Half of 2026

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Genmab reported positive Phase 3 results for its drug epcoritamab combined with lenalidomide, targeting patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The results showed statistically significant improvements, indicating a potential advancement in treatment for this patient population. This announcement is part of Genmab's interim report for the first half of 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive Phase 3 results for epcoritamab plus lenalidomide.
  • Statistically significant outcomes in DLBCL patients.
  • Potential for improved treatment options in oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+17%
120-day peak, hindsight
Typical move
1.4%
average across 7 past catalysts
Lead asset
Acasunlimab
Phase 1 · Solid Tumor

Full Press Release Details

August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant

Frequently Asked Questions

What were the results of Genmab's Phase 3 trial?

Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide.

What condition does epcoritamab target?

Epcoritamab targets relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

When was Genmab's interim report released?

The interim report was released on August 6, 2026.

What was significant about the trial results?

The trial results demonstrated statistically significant improvements.

ShareAdd on Google
Tags: GMAB Viatris Investor Conferences Healthcare Genmab epcoritamab DLBCL lenalidomide clinical trial
Last updated: Aug 6, 2026

Biotech snapshot

Lead asset
AcasunlimabPhase 1
Solid Tumor →

Catalyst track record

+17%
best trade around GMAB's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for GMAB.

See every catalyst's timing & PoA →